CoChat

Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression

Open access
Brunoni, André R., Padberg, Frank, Vieira, Erica Leandro Marciano, Teixeira, Antônio Lucio, Carvalho, André F., Lotufo, Paulo Andrade, Gattaz, Wagner F., Benseñor, Isabela Martins · 2018 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
Cited by 53

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: Transcranial direct current stimulation (tDCS) holds promise as a therapeutic intervention for major depressive disorder (MDD). A more precise understanding of its underlying mechanisms may aid in the identification of subsets of patients responsive to tDCS within the context of precision psychiatry. Objective: In this ancillary investigation of the Escitalopram vs. Electrical Current Therapy for Treating Depression Clinical Study (ELECT‐TDCS), we investigated whether plasma levels of several cytokines and neurotrophic factors associated with major depression or antidepressant response predicted tDCS effects. Methods: We examined, in 236 patients at 3 timepoints during a 10‐week treatment course, plasma levels of nerve growth factor (NGF), brain‐derived (BDNF), glial‐cell line derived neurotrophic factor (GDNF), the interleukins (IL) IL‐1ß, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐18, IL‐33, tumor necrosis factor‐alpha (TNF‐alpha), and its soluble receptors sTNFr1 and sTNFr2. General linear models and mixed‐models analyses of variance were used to respectively assess whether plasma levels of these molecules (1) predicted tDCS antidepressant improvement and (2) changed over time. Results: After correction for multiple comparisons (false discovery rate method), NGF baseline levels predicted early depression improvement for tDCS vs. escitalopram, whilst other biomarkers did not significantly predict treatment improvement. The levels of IL12p70, IL10, IL‐1ß, IL‐8 and sTNFr1 decreased over time, regardless of allocation group and clinical response. Conclusion: In general, peripheral biomarkers were not associated with the outcome. The post‐hoc finding of baseline NGF levels predicting early depression improvement for tDCS should be explored in further studies. HighlightsBlood inflammation and neurotrophic factors biomarkers of ELECT‐TDCS were examined.Data were collected in 236 patients at 3 timepoints.Biomarkers decreased over time, regardless of intervention group or clinical response.BDNF was not associated with treatment response or predicted tDCS effects.Among the 13 molecules analyzed, NGF predicted early antidepressant tDCS response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2018.06.003

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 53

Metadata

Authors
Brunoni, A. R., Padberg, F., Vieira, E. L. M., Teixeira, A. L., Carvalho, A. F., Lotufo, P. A., Gattaz, W. F., & Benseñor, I. M.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2018-08
Volume
86
Pages
211-217
ISSN
0278-5846 (ISSN-L)
OpenAlex
W2807701404
Cited by
53
References
18
FWCI
2.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. https://app.cochat.ai/papers/10.1016/j.pnpbp.2018.06.003
The paper
Brunoni, A. R., Padberg, F., Vieira, E. L. M., Teixeira, A. L., Carvalho, A. F., Lotufo, P. A., Gattaz, W. F., & Benseñor, I. M. (2018). Plasma biomarkers in a placebo-controlled trial comparing tDCS and escitalopram efficacy in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2018.06.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.